StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.78−0.40 (-2.33%)

Close on Nov 18, 2026Market cap $1.91BP/E –Yield –

Immunome revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Immunome's revenue for the twelve months ending Mar 31, 2026 was $4.02M, down 63.3% year over year. For fiscal 2025 it was $6.94M, down 23.2% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.94M-23.2%
FY2024Dec 31, 2024$9.04M-35.5%
FY2023Dec 31, 2023$14.02M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$4.02M+69.8%
Q1 FY2025Mar 31, 2025$2.93M+184.4%
Q4 FY2024Dec 31, 2024$2.74M-28.4%
Q3 FY2024Sep 30, 2024$2.91M-18.4%
Q2 FY2024Jun 30, 2024$2.36M-44.5%
Q1 FY2024Mar 31, 2024$1.03M-56.5%
Q4 FY2023Dec 31, 2023$3.83M–
Q3 FY2023Sep 30, 2023$3.57M–
Q2 FY2023Jun 30, 2023$4.26M–
Q1 FY2023Mar 31, 2023$2.36M–

More Immunome figures

See a number that looks wrong?